Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA:688266)

China flag China · Delayed Price · Currency is CNY
110.34
-0.98 (-0.88%)
Dec 5, 2025, 3:00 PM CST
66.17%
Market Cap 29.21B
Revenue (ttm) 742.28M
Net Income (ttm) -133.34M
Shares Out 264.71M
EPS (ttm) -0.50
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,404,945
Average Volume 2,338,891
Open 112.43
Previous Close 111.32
Day's Range 107.55 - 112.43
52-Week Range 58.00 - 134.17
Beta 0.20
RSI 56.67
Earnings Date Oct 31, 2025

About SHA:688266

Suzhou Zelgen Biopharmaceuticals Co., Ltd. researches and develops, manufactures, and sells medicines in the People's Republic of China. It offers donafenib tablets; recombinant human thrombin for topincal use; jacktinib tablets; and recombinant human thyroid-stimulating hormone for injection; obeticholic acid magnesium tablets; ZG19018 tablets; ZG005 powder for injection; and alkotinib capsules for the treatment of liver cancer, non-small cell lung cancer, small cell lung cancer, colorectal cancer, thyroid cancer, and neuroendocrine cancer, as... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2009
Employees 910
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 688266
Full Company Profile

Financial Performance

In 2024, SHA:688266's revenue was 532.95 million, an increase of 37.91% compared to the previous year's 386.44 million. Losses were -137.83 million, -50.52% less than in 2023.

Financial Statements

News

There is no news available yet.